William Blair downgraded Charles River (CRL) to Market Perform from Outperform without a price target “There is simply too much working against Charles River in the near term to make the stock ...
Shares for Charles River Laboratories slipped after the company said it expects revenue to decline in 2025. Shares of the Massachusetts-based pharmaceutical company were recently down 6% to $178.50 in ...
Apollo for Biologics: Provides a centralized platform to submit sample submission forms, track samples, and exchange documents all in one place, ensuring accuracy and saving time.
Results that may be inaccessible to you are currently showing.